Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

465 ARTÍCULOS , VIENDO DEL 331 AL 345

Memory loss in Alzheimer's disease

Jahn H.

Dialogues Clin Neurosci. 2013 Dec;15(4):445-54. doi: 10.31887/DCNS.2013.15.4/hjahn.

Trait, state, and mechanism: looking back, looking forward, and understanding why

Lovestone S.

J Alzheimers Dis. 2013;33 Suppl 1:S23-33. doi: 10.3233/JAD-2012-129014.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

At the end of a very hard day, people find some reason to believe

Robert P.

J Alzheimers Dis. 2013;34(1):295-6. doi: 10.3233/JAD-121637.

Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study

Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc'h K, Schraen S, Buée L, Pasquier F, Hugon J, Touchon J, Lehmann S.

J Alzheimers Dis. 2013;34(1):297-305. doi: 10.3233/JAD-121549.

Blood transcriptomic biomarkers of Alzheimer's disease patients treated with EHT 0202

Désiré L, Blondiaux E, Carrière J, Haddad R, Sol O, Fehlbaum-Beurdeley P, Einstein R, Zhou W, Pando MP.

J Alzheimers Dis. 2013;34(2):469-83. doi: 10.3233/JAD-121501.

Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm

Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, Pawelec G.

Discov Med. 2013 Jan;15(80):33-42.

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall AE, Carter SF, Schöll M, Choo IH, Nordberg A, Scheltens P, Frisoni GB.

Neurology. 2013 Mar 12;80(11):1048-56. doi: 10.1212/WNL.0b013e3182872830. Epub 2013 Feb 6.

Genetic study of neurexin and neuroligin genes in Alzheimer's disease

Martinez-Mir A, González-Pérez A, Gayán J, Antúnez C, Marín J, Boada M, Lopez-Arrieta JM, Fernández E, Ramírez-Lorca R, Sáez ME, Ruiz A, Scholl FG, Real LM.

J Alzheimers Dis. 2013;35(2):403-12. doi: 10.3233/JAD-122257.

Imaging epigenetics in Alzheimer's disease

Lista S, Garaci FG, Toschi N, Hampel H.

Curr Pharm Des. 2013;19(36):6393-415. doi: 10.2174/13816128113199990370.

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals

Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ.

J Neurosci. 2013 Mar 27;33(13):5553-63. doi: 10.1523/JNEUROSCI.4409-12.2013.

Effect of cognitive reserve markers on Alzheimer pathologic progression

Lo RY, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):343-50. doi: 10.1097/WAD.0b013e3182900b2b.

BIN1 gene rs744373 polymorphism contributes to Alzheimer's disease in East Asian population

Liu G, Zhang S, Cai Z, Li Y, Cui L, Ma G, Jiang Y, Zhang L, Feng R, Liao M, Chen Z, Zhao B, Li K.

Neurosci Lett. 2013 Jun 7;544:47-51. doi: 10.1016/j.neulet.2013.02.075. Epub 2013 Apr 6.

Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease

Tiedt HO, Lueschow A, Winter P, Müller U.

Neurosci Lett. 2013 Jun 7;544:115-8. doi: 10.1016/j.neulet.2013.03.056. Epub 2013 Apr 10.

Smell identification function as a severity and progression marker in Alzheimer's disease

Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S.

Int Psychogeriatr. 2013 Jul;25(7):1157-66. doi: 10.1017/S1041610213000446. Epub 2013 Apr 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias